- Home
- CANF vs MNDR Comparison
CANF vs MNDR Comparison
Compare CANF & MNDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- MNDR
- Stock Information
- Founded
- CANF 1994
- MNDR 2016
- Country
- CANF Israel
- MNDR Singapore
- Employees
- CANF N/A
- MNDR N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- MNDR
- Sector
- CANF Health Care
- MNDR
- Exchange
- CANF Nasdaq
- MNDR Nasdaq
- Market Cap
- CANF 9.6M
- MNDR 9.3M
- IPO Year
- CANF N/A
- MNDR 2024
- Fundamental
- Price
- CANF $0.39
- MNDR $1.88
- Analyst Decision
- CANF Strong Buy
- MNDR
- Analyst Count
- CANF 3
- MNDR 0
- Target Price
- CANF $10.50
- MNDR N/A
- AVG Volume (30 Days)
- CANF 204.7K
- MNDR 29.8K
- Earning Date
- CANF 11-27-2025
- MNDR 10-31-2025
- Dividend Yield
- CANF N/A
- MNDR N/A
- EPS Growth
- CANF N/A
- MNDR N/A
- EPS
- CANF N/A
- MNDR N/A
- Revenue
- CANF $560,000.00
- MNDR $7,646,739.00
- Revenue This Year
- CANF $461.72
- MNDR $608,852.40
- Revenue Next Year
- CANF N/A
- MNDR N/A
- P/E Ratio
- CANF N/A
- MNDR N/A
- Revenue Growth
- CANF N/A
- MNDR N/A
- 52 Week Low
- CANF $0.37
- MNDR $1.81
- 52 Week High
- CANF $2.35
- MNDR $40.00
- Technical
- Relative Strength Index (RSI)
- CANF 20.76
- MNDR 31.24
- Support Level
- CANF $0.37
- MNDR $1.85
- Resistance Level
- CANF $0.42
- MNDR $3.19
- Average True Range (ATR)
- CANF 0.02
- MNDR 0.18
- MACD
- CANF 0.00
- MNDR -0.12
- Stochastic Oscillator
- CANF 14.33
- MNDR 4.35
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About MNDR Mobile-health Network Solutions Class A Ordinary Shares
Mobile-health Network Solutions is a company engaged in providing telehealth solutions in terms of various matrices, such as the number of patient consultations per day and the ranking of its mobile application. It provides services on its MaNaDr platform, which is accessible via mobile application and website. The MaNaDr platform is a platform designed and created by doctors, for doctors and users, equipped with services like consultations with doctors, e-commerce pharma store, and others. The company's operating segments are Telemedicine and other services which is also its key revenue generating segment, and Sale of medicine and medical devices. Geographically, it derives revenue from Singapore.